WednesdayApr 06, 2022 2:46 pm

Study Finds That Exercise May Reduce Symptoms of Depression

New studies have found that exercising for 30 minutes may boost the benefits of therapy and decrease symptoms of depression for at least an hour and 15 minutes post workout. The studies were carried out by Iowa State University researchers, led by Professor Jacob Myer, who was also the lead author. The objective of the research was to find out how exercising influenced the symptoms of depression. For their first study, the researchers recruited 30 adults who experienced major depressive episodes. Each participant was required to fill out surveys, which included the scales used to measure a number of cognitive…

Continue Reading

WednesdayApr 06, 2022 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Increasing Rare Cannabidiol Product Portfolio, Revenues

InMed Pharmaceuticals is a Canadian clinical-stage drug development company focused on the development of rare cannabinoids and their synthetic counterpoints for B2B sales and pharmaceutical potential InMed expects to have rare cannabinoids CBDV and THCV available for B2B sale to the health and wellness market in the coming months, following on the heels of its CBC and CBT products The company recently reported its first revenues from CBC sales in the wake of its acquisition of rare cannabinoids manufacturer BayMedica late last year The company is also working to develop synthetic CBN cannabinoids as potential medical treatments for select conditions,…

Continue Reading

TuesdayApr 05, 2022 2:48 pm

Researchers Explain the Link Between Diabetes, Hypertension

A new study conducted by a team of researchers from the Universities of Bristol and Auckland has discovered why most patients with hypertension also suffer from diabetes. Hypertension is also referred to as high blood pressure and is known to increase an individual’s risk of stroke and heart disease, among other indications. It can also cause severe health complications, sometimes leading to death. On the other hand, diabetes is a chronic health condition that develops when an individual’s body can’t effectively use the insulin it produces or when their pancreas doesn’t produce enough insulin. The condition, which is sometimes referred…

Continue Reading

TuesdayApr 05, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Begins Recruitment for Study Measuring Ketamine’s Psychedelic Effect

Cybin-sponsored study will use Kernel Flow, Kernel’s quantitative neuroimaging. Company hopes to learn more about impact ketamine has on brain activity, overall mental well-being. Study results may lead to future studies supporting CYBN’s mission to develop psychedelics into therapeutics. Cybin’s (NEO: CYBN) (NYSE American: CYBN) efforts to transform the mental-health treatment landscape have reached a key milestone: the company is actively recruiting participants for its upcoming feasibility study using Kernel Flow, Kernel’s quantitative neuroimaging technology (https://ibn.fm/9aSxc). “The feasibility study using Kernel Flow offers an opportunity for researchers and our study participants to quantifiably gather information on a psychedelic experience,” said Cybin…

Continue Reading

TuesdayApr 05, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leveraging Growth Across Multiple Markets Including Mental Health, Healthcare IT

Mydecine was founded in 2020 as a response to the lack of innovation addressing mental health treatment and the therapeutic possibilities represented by psychedelic compounds and other novel molecules The world is experiencing a shortage of mental health resources, while faced with an increase in mental health issues on the heels of the pandemic Mydecine is leveraging the psychedelic drugs market, the PTSD market, and healthcare IT markets – with potential growth across all avenues In the first year of the COVID-19 pandemic, the prevalence of anxiety and depression worldwide increased by 25%, according to a World Health Organization (“WHO”)…

Continue Reading

MondayApr 04, 2022 10:54 am

Reddit Analysis Finds Similarities Between Nonsuicidal Self-Harm Experiences, Addiction

New research has found that the experiences of people who talked about and reported nonsuicidal self-injury on Reddit are similar to individuals who have been diagnosed with substance use disorder. Individuals who posted on a self-injury forum titled r/self-harm in 2010–2019 cited an increase in tolerance or severity and often referred to their activities as an addiction. These are terms that are regularly used by individuals recovering from substance use disorders. Figures estimate that about 7% of adults, 12% of young adults and 17% of adolescents report a history of nonsuicidal self-injury. Currently, there exists no standard approach for the…

Continue Reading

MondayApr 04, 2022 9:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC

The three-day event showcased CNS through corporate presentation, fireside chat, and live question and answer sessions  CNS has been granted both Orphan Drug Designation and Fast Track status from the FDA for Berubicin in 2020 and 2021, respectively CNS initiated a potentially pivotal global trial of Berubicin for recurrent Glioblastoma Multiforme (“GBM”) with the dosing of the first patients in the trial during 3Q 2021 At the end of 2021, CNS gained approval from swissethics to initiate trial sites in Switzerland for the global trial of Berubicin Virtual event participation can be found on the CNS website under “Events” CNS…

Continue Reading

FridayApr 01, 2022 2:39 pm

Timing of Food Intake Impacts Mental Health, Study Says

New research has discovered that the time at which an individual consumes food may impact their mental health. Focusing on what you eat is important for your overall health, but did you know that paying some attention to when you eat may also be good for your mental health? Research has found that abnormal eating times may contribute to poor mental health, including anxiety and depression, as well as weight gain and cardio-metabolic illnesses. Researchers believe that the circadian clock, which aligns the internal processes in our body at optimal times during the day based on environmental cues such as…

Continue Reading

ThursdayMar 31, 2022 3:05 pm

Study Finds That Younger Pediatric Brain Cancer Patients Have Poorer Outcomes Than Older Patients

A new study has found that children with brain tumors, particularly those who are three months and younger, have a significantly lower rate of survival in comparison to those aged between 1 and 19. The study was carried out by researchers at the University of Colorado Cancer Center, led by associate professor of pediatric hematology/oncology Adam Green. The researchers reported their findings in the “Journal of Neuro-Oncology.” For their study, the researchers obtained data from more than 14,000 children, aged 19 years and younger, who had been diagnosed with brain tumors; the information came from the Surveillance, Epidemiology and End…

Continue Reading

ThursdayMar 31, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Reiterates Commitment to Operational Excellence, Advancing Berubicin Recognition

In a video message to shareholders, CEO John Climaco detailed the operational and clinical progress made by lead drug candidate Berubicin despite market volatility and share price fluctuations CNS is currently enrolling patients into a potentially pivotal global drug trial of Berubicin for recurrent glioblastoma multiforme Interim analysis of the trial is currently expected as early as the first quarter of 2023, once 30-50% of trial patients have been on the study for six months CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotech company specializing in developing novel treatments for primary and metastatic cancers of the brain and central nervous system,…

Continue Reading

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000